2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Women’s Health, Workforce, Adverse Events, Biological Processes, Apoptosis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3744 Deep molecular response and treatment-free remission with dasatinib plus venetoclax in newly diagnosed chronic myeloid leukemia

Dany Nassar, MD, Elias Jabbour, MD2, Fadi G. Haddad, MD3, Bing Z Carter, PhD4, Yesid Alvarado Valero, MD5, Lucia Masarova, MD6, Naval Daver, MD7, Naveen Pemmaraju, MD8, Nicholas Short, MD9, Jeffrey A Skinner10, Jennifer Veazie11, Tapan Kadia I, MD12, Maria Villatoro13, Gautam Borthakur, MD14, Guillermo Garcia-Manero, MD15, Farhad Ravandi, MD16, Ghayas C. Issa, MD17, Michael Andreeff, MD, PhD18, Hagop Kantarjian, MD19
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction

Dual inhibition of the BCR::ABL1 tyrosine kinase and BCL-2 may increase the depth and durability of molecular responses in chronic-phase chronic myeloid leukemia (CML-CP), potentially facilitating treatment-free remission (TFR). This updated analysis evaluated durable deep molecular response (DMR), TFR, and long-term outcomes following frontline treatment with dasatinib plus venetoclax. 

Methods

This phase 2 trial (NCT02689440) included patients with newly diagnosed CML-CP or accelerated-phase CML defined solely by clonal evolution. Patients received oral dasatinib 50 mg daily for 3 courses, followed by venetoclax beginning with course 4 for 3 years. After completion of combination therapy, patients continued dasatinib alone. Molecular responses were assessed using BCR::ABL1 on the International Scale (IS); MMR, MR4, and MR4.5 were defined as BCR::ABL1 ≤0.1%, ≤0.01%, and ≤0.0032%, respectively. EFS was measured from treatment initiation to loss of complete hematologic response, loss of major cytogenetic response, transformation to accelerated or blast phase, or death, whichever occurred first. Transformation-free survival (TFS) was measured from treatment initiation to transformation or death, and OS to death from any cause. TFR was measured from TKI discontinuation to loss of MMR or TKI resumption, whichever occurred first. Survival and TFR were estimated using the Kaplan–Meier method. 

Results

A total of 66 patients were treated with the combination of dasatinib and venetoclax, the median age was 45.5 years (range, 23–72). Sokal risk was low in 47 (71%), intermediate in 17 (26%), and high in 2 (3%) patients. The cumulative rates of MMR, MR4, and MR4.5 by 12 months of therapy were 68.8%, 48.5% and 48.5% respectively. The respective 4-year cumulative rates were 98.4%, 85.1%, and 77.9%. One patient lost CCyR, one patient did not achieve CCyR after 18 months of therapy, and one patient lost MCyR, translating into a 4-year EFS rate of 97%. There were no deaths or transformations observed, with 4-year OS and TFS rates of 100%.

Nine patients (14%) attempted TFR after a median of 67 months of TKI therapy (range, 55-84) and 61 months of sustained MR4 or deeper (range, 48-82). All patients had sustained MR4 or deeper for more than 4 years and 5 had it for more than 5 years. At discontinuation, 5 patients were asymptomatic, while the remaining 4 were experiencing low-grade treatment-related adverse events of fatigue, generalized bone pain, pleural effusion, and shortness of breath, in one patient each. At a median follow-up of 15 months after TKI discontinuation, 5 of 9 patients remained in TFR. The estimated 12-month TFR rate was 50.0% (95% CI, 11.1%–80.4%). 4 out of 5 patients who did not lose MMR had more than 5 years of MR4 or deeper response before stopping therapy. Four patients lost MMR within 4 to 15 months from stopping therapy. Three restarted TKI therapy (2 restarted dasatinib and 1 asciminib) and all regained MMR and subsequently MR4.5 within 1 year; MR4.5 was regained after 3, 3, and 7 months. One patient remained off TKI despite loss of MMR and a BCR::ABL1 level of 0.5% IS; this patient remained asymptomatic and maintained a complete cytogenetic response. No transformation or CML-related death occurred during the TFR period.

Conclusion

Dasatinib plus venetoclax produced high cumulative molecular response rates and favorable long-term survival, with no deaths or transformations observed. Treatment discontinuation was feasible in patients with sustained deep molecular response, with a 12-month TFR rate of 50%. Longer follow-up after more patients discontinue therapy is needed to better characterize the TFR outcomes with this combination.

Dany Nassar, MD: No relevant conflicts of interest to declare.